Regulatory approval is only one marker of success for biotherapeutics. Biotherapeutics must also be commercially feasible. Too high a price tag can lead to limited availability to the targeted patient ...

Developing a new therapeutic molecule is a complex and expensive process with a high risk of failure at each step. Research suggests that aggregate costs per commercialized drug (including failures) ...